PTC Therapeutics Inc
F:P91
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
P
|
PTC Therapeutics Inc
F:P91
|
US |
|
Vaudoise Assurances Holding SA
SIX:VAHN
|
CH |
|
P
|
Precigen Inc
F:I5X
|
US |
|
F
|
First Tin PLC
F:1SN
|
UK |
|
Prosegur Compania de Seguridad SA
F:PRHA
|
ES |
|
AFC Gamma Inc
F:0FG
|
US |
Wall St Price Targets
P91 Price Targets Summary
PTC Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for P91 is 53.05 EUR with a low forecast of 36.62 EUR and a high forecast of 77.39 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is P91's stock price target?
Price Target
53.05
EUR
According to Wall Street analysts, the average 1-year price target for P91 is 53.05 EUR with a low forecast of 36.62 EUR and a high forecast of 77.39 EUR.
What is the Revenue forecast for PTC Therapeutics Inc?
Projected CAGR
2%
Over the last 13 years, the compound annual growth rate for Revenue has been 35%. The projected CAGR for the next 8 years is 2%.
What is the Operating Income forecast for PTC Therapeutics Inc?
Projected CAGR
-4%
The compound annual growth rate for Operating Income over the next 8 years is -4%.
What is the Net Income forecast for PTC Therapeutics Inc?
Projected CAGR
-3%
Over the last 13 years, the compound annual growth rate for Net Income has been 70%. The projected CAGR for the next 8 years is -3%.
